Eisai Co. Ltd. $4523.T shares climbed significantly in Tokyo after the US Food and Drug Administration (FDA) authorized the first-ever blood test for Alzheimer’s disease diagnosis. This approval refocused investor attention on pharmaceutical manufacturers positioned to benefit from accelerated demand for Alzheimer’s therapies.